Max D. Overath

This study designs de novo single-domain antibodies against cobra neurotoxin and shows they protect mice from lethal venom toxicity.

This paper develops a pipeline combining yeast screening and AlphaFold3 to accelerate discovery of multi-target antibodies, finding that structural predictions improve binding specificity and solubility.

This study uses synthetic coevolution to explore mutational trajectories between neutralizing antibodies and SARS-CoV-2 variants, revealing antagonistic and compensatory mutations.

The paper analyzes 3,766 binders to identify predictive features for experimental success in de novo binder design, showing that AF3-derived metrics improve prediction accuracy.

This paper designs de novo pMHC binders using generative models to create T cell-based cancer therapeutics with high specificity and minimal cross-reactivity.

The paper introduces a simplified method for amplifying plasmid DNA libraries using rolling circle amplification and endonuclease treatment to improve transformation efficiency in E. coli and S. cerevisiae.